Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dogwood Therapeutics, Inc (DWTX : NSDQ)

• Company Description    Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $1.79 Daily Weekly Monthly 20 Day Moving Average: 92,470 shares Shares Outstanding: 33.63 (millions) Market Capitalization: $60.20 (millions) Beta: 1.68 52 Week High: $9.50 52 Week Low: $1.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.86% 21.61% 12 Week -35.14% -40.04% Year To Date -56.97% -60.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 44 MILTON AVENUE - ALPHARETTA,GA 30009 USA ph: 866-620-8655 fax: - ir@dwtx.com http://www.dwtx.com

• General Corporate Information    Officers Greg Duncan - Chairman and Chief Executive Officer Ralph Grosswald - Chief Financial Officer; Corporate Secretary and T Ralph Grosswald - Senior Vice President Abel De La Rosa - Director David Keefer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92829J203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 33.63 Most Recent Split Date: 10.00 (0.04:1) Beta: 1.68 Market Capitalization: $60.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.44% vs. Previous Quarter: 42.31% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -108.57 12/31/25 - -2,027.44 09/30/25 - - ROA 03/31/26 - -30.28 12/31/25 - -31.29 09/30/25 - -35.11 Current Ratio 03/31/26 - 5.86 12/31/25 - 2.76 09/30/25 - 4.49 Quick Ratio 03/31/26 - - 12/31/25 - 2.76 09/30/25 - 4.49 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 2.40 12/31/25 - 2.33 09/30/25 - -14.42 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©